Retatrutide

Clinical Trials

Retatrutide (LY3437943)

Aliases
LY3437943, Triple-G
Administration
Subcutaneous injection (once weekly)

Documented benefits

Tier 1 · Peer-reviewed / regulatory

Benefit categories

Weight Loss & Metabolism

Retatrutide's defining research application — the only triple-hormone-receptor agonist in this database.

Weight loss

Produced the largest average weight loss recorded for any injectable compound in trials to date, via three combined hormone pathways.

Blood sugar regulation

Improves insulin sensitivity and blood sugar control through combined GIP and GLP-1 receptor activation.

Increased energy expenditure

Its added glucagon receptor activation is unique among GLP-1-class drugs, directly raising resting calorie burn.